Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma

Molecular Cancer Therapeutics

Volumn 8, Issue 7, 2009, Pages 2067-2075

  Koomoa, Dana Lynn T ^a   Borsics, Tamas ^a   Feith, David J ^d   Coleman, Craig C ^a,c   Wallick, Christopher J ^a,e   Gamper, Ivonne ^a,f   Pegg, Anthony E ^d   Bachmann, André S ^a,b,c  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMIDINO 1 INDANONE 2' AMIDINOHYDRAZONE; ADENOSYLMETHIONINE DECARBOXYLASE; ADENOSYLMETHIONINE DECARBOXYLASE INHIBITOR; DECARBOXYLASE INHIBITOR; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SAM 486A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REGULATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; POLYAMINE METABOLISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENOSYLMETHIONINE DECARBOXYLASE; AMIDINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; INDANS; NEUROBLASTOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; S-ADENOSYLMETHIONINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67651183766     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1217     Document Type: Article

References (26)

1. Davidson NE, Hahm HA, McCloskey DE, Woster PM, Casero RA, Jr. Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr Relat Cancer 1999;6:69-73.
2. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of postradiotherapy chemotherapy with combination α-difluoromethylornithine- PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003;9: 981-90.
3. Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with α-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000;6:3878-84.
4. McCann PP, Pegg AE. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther 1992;54:195-215.
5. Meyskens FL, Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-51.
6. Takahashi Y, Mai M, Nishioka K. α-Difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model. Int J Cancer 2000;85:243-7.
7. Regenass U, Caravatti G, Mett H, et al. New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity. Cancer Res 1992;52:4712-8.
8. Regenass U, Mett H, Stanek J, Mueller M, Kramer D, Porter CW. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res 1994;54:3210-7.
9. Stanek J, Caravatti G, Frei J, et al. 4-Amidinoindan-1-one 2′-amidinohydrazone: a new potent and selective inhibitor of S-adenosylmethionine decarboxylase. J Med Chem 1993;36:2168-71.
10. Svensson F, Mett H, Persson L. CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme. Biochem J 1997;322:297-302.
11. Dorhout B, Odink MF, de Hoog E, Kingma AW, van der Veer E, Muskiet FA. 4-Amidinoindan-1-one 2′-amidinohydrazone (CGP 48664A) exerts in vitro growth inhibitory effects that are not only related to S-adenosylmethionine decarboxylase (SAMdc) inhibition. Biochim Biophys Acta 1997;1335:144-52.
12. Dorhout B, te Velde RJ, Ferwerda H, Kingma AW, de Hoog E, Muskiet FA. In vivo effects of 4-amidinoindan-1-one 2′-amidinohydrazone (CGP 48664A) and α-difluoromethylornithine (DFMO) on L1210 growth, cell-cycle phase distribution and polyamine contents. Int J Cancer 1995;62:738-42.
13. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 2003;4:537-64.
14. Eskens FA, Greim GA, van Zuylen C, et al, European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. Clin Cancer Res 2000;6:1736-43.
15. Pless M, Belhadj K, Menssen HD, et al. Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study. Clin Cancer Res 2004;10:1299-305.
16. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
17. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
18. Goldman SC, Chen CY, Lansing TJ, Gilmer TM, Kastan MB. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol 1996;148:1381-5.
19. Hosoi G, Hara J, Okamura T, et al. Low frequency of the p53 gene mutations in neuroblastoma. Cancer 1994;73:3087-93.
20. 1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 2005;24:5606-18.
21. Slack A, Chen Z, Tonelli R, et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A 2005;102:731-6.
22. Koomoa DL, Yco LP, Borsics T, Wallick CJ, Bachmann AS. Ornithine decarboxylase inhibition by α-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 2008;68:9825-31.
23. Tampio M, Loikkanen J, Myllynen P, Mertanen A, Vahakangas KH. Benzo(a)pyrene increases phosphorylation of p53 at serine 392 in relation to p53 induction and cell death in MCF-7 cells. Toxicol Lett 2008;178:152-9.
24. Bhattacharya S, Ray RM, Johnson LR. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal 2009;21:509-22.
25. Haines DS. The mdm2 proto-oncogene. Leuk Lymphoma 1997;26:227-38.
26. Erhardt P, Tomaselli KJ, Cooper GM. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. J Biol Chem 1997;272:15049-52.